Figure 5
From: Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy – a case report
In vitro cytolytic activity of patient-derived PBMNC derived from L1 to L6 and L7 to L9 against K562 cells (A) and autologous tumor (B). The lytic activity of patient-derived PBMNC before and after stimulation with TKD/IL-2 was determined by standard granzyme B ELISPOT. Filled circles indicate the cytolytic activity of unstimulated PBMNC, open circles that of TKD/IL-2 stimulated PBMNC. Due to technical problems data from L2 are not available. Viability of the tumor target cells in each assay was > 95%.